Empagliflozin to elderly and obese patients with cardiovascular disease (EMPIRE II): A randomized controlled trial

Odense University Hospital - Department of Cardiology0 个研究点目标入组 204 人开始时间: 2021年4月7日最近更新: 2021年7月21日

适应症

试验速览

暂无简介。

•(1)Age 60-84 years
•(2) Bodymass index >28 kg/m2
•(3) Documented risk factors for developing heart failure, i.e. one-of following :
•(3a) Hypertension
•(3b) Documented ischemic heart disease
•(3c) Stroke or transitory cerebral ischemia
•(3d) Chronic kidney disease with GFR 30-45 ml/min/1,72m2
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 104

•(1) Diabetes mellitus (type 1 or 2)
•(2) Heart failure with ejection fraction <40%
•(3) Inability to perform exercise test
•(4) Dementia
•(5) Non-compliance
•(6) Substance abuse
•(7) GFR <30 ml/min/1,72m2
•(8) Severe chronic obstructive pulmonary disease (FEV1< 50% expected value)
•(9) Permanent atrial fibrillation
•(10) Severe peripheral artery disease
•(11) Cancer treatment within one year beside prostate cancer and basal cell carcinoma
•(12) Severe aortic or mitral valve disease
•(13) Acute hospital admission within 30 days
•(14) Participation in other pharmacological study
•(15) Pregnancy
•(16) Breastfeeding

发起方

Odense University Hospital - Department of Cardiology